Number of Therapeutic Peptides in Clinical Study Has Nearly Doubled Since the 1990s, According to Tufts Center for the Study of Drug Development
20 mai 2009 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 20, 2009) - Since 2000, the number of therapeutic peptides
in clinical study has nearly doubled the 1990s rate, due in part to
advances in synthesis, delivery, and...
Pharmaceutical Licensing Success Is Tied to Clarity of Strategy on Both Sides, According to Tufts Center for the Study of Drug Development
16 avr. 2009 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - April 16, 2009) - Pharmaceutical firms looking to license new drug
candidates from other firms will improve their chances of achieving a
successful alliance if they focus on...
Three-Quarters of U.S. Health Plans Reimburse for Off-Label Uses of Prescription Drugs, According to Tufts Center for the Study of Drug Development
10 mars 2009 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 10, 2009) - Reflecting recent rapid growth of off-label
prescribing of prescription drugs, 75 percent of all health plans in the
United States now reimburse patients...
Drug Developers Looking to Learn as Much as Possible in Phase I Trials, According to Tufts Center for the Study of Drug Development
27 janv. 2009 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 27, 2009) - Under pressure to develop new medicines more
quickly and at lower cost, drug sponsors are looking to answer as many
questions as possible in Phase I,...
The U.S. Remains Preferred Market for Launching New Products, According to Tufts Center for the Study of Drug Development
12 nov. 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 12, 2008) - While the number of annual new drug approvals in
the United States has declined during the past decade, the U.S. remains the
preferred market for...
Clinical Trial Design Holds Key to Improved Drug Development Efficiency, According to Tufts Center for the Study of Drug Development
30 oct. 2008 10h10 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 30, 2008) - Improved protocol design, perhaps more than any
other drug development stratagem, holds the key to faster and more
efficient development, according to...
Fast Track Drugs Reach Market Sooner, According to Tufts Center for the Study of Drug Development
03 sept. 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 3, 2008) - New drugs that receive fast track designation by
the U.S. Food and Drug Administration (FDA) experience shorter clinical and
approval times compared to...
Postmarketing Studies Are Becoming the Norm in the U.S., Europe, and Japan, According to Tufts Center for the Study of Drug Development
10 juil. 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 10, 2008) - Post-approval study commitments, in which drug
developers, as a condition of regulatory approval, agree to conduct
research on newly marketed prescription...
Effective Drug Development Metrics Link Operations With Strategy, According to Tufts Center for the Study of Drug Development
10 juin 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - June 10, 2008) - Research-based drug companies looking to
streamline the development of new medicinal products should adopt metrics
that link their R&D activities with...
Medicare Prescription Drug Plans Not Fully Compliant With Federal Regulations, According to Tufts Center for the Study of Drug Development
06 mai 2008 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 6, 2008) - A new study by the Tufts Center for the Study of
Drug Development has found that Medicare prescription drug plans that came
into being following the landmark...